Publication:
Implications of maraviroc and/or rapamycin in a mouse model of fragility.

dc.contributor.authorPerez-Martinez, Laura
dc.contributor.authorRomero, Lourdes
dc.contributor.authorMuñoz-Galvan, Sandra
dc.contributor.authorVerdugo-Sivianes, Eva M
dc.contributor.authorRubio-Mediavilla, Susana
dc.contributor.authorOteo, Jose A
dc.contributor.authorCarnero, Amancio
dc.contributor.authorBlanco, Jose-Ramon
dc.contributor.funderInstituto de Salud Carlos III (ISCIII)
dc.contributor.funderM. Economía y Competitividad of Spain
dc.contributor.funderEuropean Regional Development Fund (FEDER)
dc.contributor.funderCIBER de Cáncer
dc.date.accessioned2023-02-08T14:48:03Z
dc.date.available2023-02-08T14:48:03Z
dc.date.issued2020-04-30
dc.description.abstractAs age increases, the risk of developing fragility also increases. Improving the knowledge of frailty could contribute to maintaining the functional ability of elderly people. Interleukin (IL)-10 homozygous knockout mice (IL-10tm/tm [IL10KO]) constitute an excellent tool for the study of frailty. Because patients with frailty demonstrate an overexpression of CCR5, rapamycin (RAPA) and/or maraviroc (MVC), two molecules able to decrease CCR5 expression, were evaluated. Muscle myostatin was reduced in all the therapeutic groups but the MVC group (p MVC and RAPA show a protective role in some factors involved in frailty. More studies are needed to prove their clinical applications. Eighty male homozygous IL10KOs were randomly assigned to one of 4 groups (n= 20): i) IL10KO group (IL10KO); ii) IL10KO receiving MVC in drinking water (MVC group), iii) IL10KO receiving RAPA in drinking water (RAPA group), and finally, iv) MVC-RAPA group that received MVC and RAPA in drinking water. Blood and muscle samples were analysed. Survival analysis, frailty index calculation, and functional assessment were also performed.
dc.description.versionSi
dc.identifier.citationPérez-Martínez L, Romero L, Muñoz-Galván S, Verdugo-Sivianes EM, Rubio-Mediavilla S, Oteo JA, et al. Implications of maraviroc and/or rapamycin in a mouse model of fragility. Aging (Albany NY). 2020 Apr 30;12(9):8565-8582.
dc.identifier.doi10.18632/aging.103167
dc.identifier.essn1945-4589
dc.identifier.pmcPMC7244075
dc.identifier.pmid32353830
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244075/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.18632/aging.103167
dc.identifier.urihttp://hdl.handle.net/10668/15471
dc.issue.number9
dc.journal.titleAging
dc.journal.titleabbreviationAging (Albany NY)
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number8565-8582
dc.provenanceRealizada la curación de contenido 03/06/2025.
dc.publisherImpact Journals LLC
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.relation.projectIDCB16/12/00275
dc.relation.projectIDRTI2018-097455-B-I00
dc.relation.projectIDFRSABC007
dc.relation.projectIDPI16/00127
dc.relation.publisherversionhttps://www.aging-us.com/full/103167
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCCR5 antagonist
dc.subjectfrailty
dc.subjectmyostatin
dc.subjectrapamycin
dc.subject.decsFragilidad
dc.subject.decsSangre
dc.subject.decsInterleucinas
dc.subject.decsMaraviroc
dc.subject.decsMiostatina
dc.subject.decsAnálisis de supervivencia
dc.subject.decsSirolimus
dc.subject.meshAging
dc.subject.meshAnimals
dc.subject.meshCytokines
dc.subject.meshDisease Models, Animal
dc.subject.meshFrailty
dc.subject.meshInterleukin-10
dc.subject.meshMale
dc.subject.meshMaraviroc
dc.subject.meshMice
dc.subject.meshMice, Knockout
dc.subject.meshMuscle, Skeletal
dc.subject.meshRandom Allocation
dc.subject.meshReceptors, Chemokine
dc.subject.meshSirolimus
dc.subject.meshSurvival Rate
dc.titleImplications of maraviroc and/or rapamycin in a mouse model of fragility.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC7244075.pdf
Size:
2.07 MB
Format:
Adobe Portable Document Format